Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
Myrto Moutafi(University General Hospital Attikon), David L. Rimm(Yale University), Vesal Yaghoobi(Yale University), Sandra Martínez-Morilla(Yale University), D.C. Liebler(National Institute of Standards and Technology), Charles T. Robbins(Yale University), Joseph S. Krueger(Scripps Research Institute), Salisha Hill, Vasiliki Xirou(Yale University), Yan Song(Qilu Hospital of Shandong University), K. Bloom(Invicro (United States)), Yalai Bai(Yale University), Patricia Gaule(Yale University), Regan Fulton(Program for Appropriate Technology in Health), Aileen I. Fernandez(Yale University)
Cited by 141
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k